Endometrial Cancer Research and Education Act of 2025
Impact
The bill proposes amendments to the Public Health Service Act, directing the National Institutes of Health (NIH) to intensify research efforts and support programs focusing on endometrial cancer. It mandates improved communication between healthcare providers and researchers about the disparities in diagnosis and treatment faced by minority women. Additionally, the bill requires that clinical trials be inclusive of African-American women in proportion to their representation in reported incidence rates, thereby aiming to tackle the underrepresentation of minority groups in cancer research.
Summary
House Bill 5239, known as the Endometrial Cancer Research and Education Act of 2025, aims to enhance research and public education concerning endometrial cancer. This initiative acknowledges that endometrial cancer is the most common form of uterine cancer, predominantly affecting post-menopausal women, especially those aged 55 to 64. The bill identifies concerning disparities in incidence rates, particularly among African-American women, who are diagnosed with more aggressive subtypes of the disease. It underscores the urgent need for expanded research and better access to treatment across different demographics.
Contention
Potential areas of contention around HB 5239 may arise due to concerns regarding funding allocation and the effectiveness of proposed outreach programs. There may be debates over how the bill addresses existing inequalities and whether it sufficiently ensures the practical implementation of educational initiatives aimed at populations at higher risk. Critics might question the effectiveness of the educational efforts proposed under the bill and whether they will result in tangible improvements in healthcare access and outcomes for affected women.
Triple-Negative Breast Cancer Research and Education Act of 2023 This bill requires research and education activities related to triple-negative breast cancer. The cells of these breast cancers are negative for estrogen receptors, progesterone receptors, and excess HER2 protein, so they do not respond to hormonal therapy medicines or medicines that target the HER2 protein receptors. Specifically, the National Institutes of Health must conduct and support research into the disease. Additionally, the Centers for Disease Control and Prevention and the Health Resources and Services Administration must develop information about triple-negative breast cancer, including information regarding the elevated risk for minority women, for the public and for health care providers.
Recognizing the seriousness of polycystic ovary syndrome (PCOS) and expressing support for the designation of the month of September 2023 as "PCOS Awareness Month".
A resolution recognizing the seriousness of polycystic ovary syndrome (PCOS) and expressing support for the designation of September 2023 as "PCOS Awareness Month".
Recognizing the seriousness of polycystic ovary syndrome (PCOS) and expressing support for the designation of the month of September 2024 as "PCOS Awareness Month".
Recognizing the seriousness of polycystic ovary syndrome (PCOS) and expressing support for the designation of the month of September as "PCOS Awareness Month".
Requires health insurers to cover colorectal cancer screenings recommended by United States Preventive Services Task Force and eliminates cost-sharing requirements for certain colonoscopies.